• FingerMotion attributed its strong finish for Q3 2022 to strategic investments and collaborations with key players in the industry
• It hopes to carry on this performance trend into the next fiscal year, tapping into the investments and collaborations made so far
• The company also plans to capitalize on the insurtech sector while also forming new brands designed to offer mobile device protection for the Chinese market

FingerMotion (NASDAQ: FNGR), recently released its financial results for the third quarter of the 2022 financial year (“Q3 2021”), posting a 21% growth in revenue from the same period in 2020. Martin Shen, the Chief Executive officer (“CEO”) of the company, termed this a “strong finish” while also expressing his optimism for even better performance in the next fiscal year (https://ibn.fm/iWS7u). This growth for Q3 2022 was attributed to the company’s strategic investments and collaborations with key players in the industry, most notably China Mobile in the Fujian province. “The third quarter finished strong with $5.9 million in revenue and an acceleration of our top-up business,” Mr. Shen noted. “During the quarter, we were aggressive in rolling out our collaboration with China Mobile in Fujian province,” he added. Gross profit for Q3 2022 stood at $967,075, representing a 56% year-over-year growth from the same period the previous year. In addition, its Telecommunications Products and Services business posted total revenue of $2.8 million, a 580% year-over-year quarterly growth from the same period in 2020. FingerMotion closed the 2021 calendar year with significant investment into its insurtech sector. Its services agreement with Pacific Life Re, through its big data analytic division, Sapientus, coupled with its collaboration with Xuanlian Tianxia Technology and Happy Life Insurance, make it a formidable force in the Insurtech space. Mr. Shen is confident that in the new year, revenue should ramp up as the insurtech business starts to unfold, all while tapping into the big data in the insurance market that is projected to be valued at $12 billion by 2023 (https://ibn.fm/dE4dz). The company has also formed new brands designed to offer mobile device protection in China, with Beta testing already underway. Mr. Shen is optimistic that this investment will represent a significant revenue stream in the next fiscal year, even as it works on other aspects of its operations, including creating new insurance products. “Our teams are uniquely qualified to create new insurance products that push the envelope of what is possible. Our goal is to enable the creation and distribution of insurance solutions that match consumer profiles, offer more flexibility and ultimately cost savings to the consumer while at the same time creating underwriting efficiencies that will eventually drop down to the bottom line, making our collaboration particularly rewarding in the long run,” noted Mr. Shen. In January 2022, FingerMotion became the latest technology company listed on the Nasdaq Capital Market in a move that offered it great exposure within the investment community. Mr. Shen believes that this, coupled with the investments made over the 2021 calendar year, will continue to strengthen the company’s balance sheet and profitability, carrying on the trend posted in Q3 2022. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Keyfest 2022 prompted the question as to whether the Lightning Network is decentralized – the very essence of the layer 2 protocol overlay of the blockchain
• Unlike fiat currency, which is ultimately governed by The Federal Reserve, Bitcoin’s Lightning Network is comprised of nodes and channels with no direct governing body
• The success of the Lightning Network since January 2021 is driving LQwD’s drive for the new year

In a 2015 white paper draft, Joseph Poon and Thaddeus Dryja laid out the Lightning Network for the first time. Two years later, in 2017, the first transaction was made on the layer 2 payment protocol layered on top of a block-based cryptocurrency. Since then, and especially in the past year, the Lightning Network has grown considerably, making transactions among nodes faster and with lower fees. The Lightning Network was among the topics of discussion at Keyfest 2022, organized on January 5-7 by Casa, a Bitcoin custody provider and personalized key manager. At its second edition this year, Keyfest is a virtual festival celebrating the past, present, and future of personal keys. Here, the brightest minds in Bitcoin come together for three days of conversation and workshops discussing a future where everyone owns their wealth, identity, and data. The blockchain itself was created as a decentralized infrastructure, one free of control from the government and other central authorities. The fiat currency system in the United States begins with one central node – The Federal Reserve. The Federal Reserve has the power over the entire process, but it trickles down into supporting nodes and channels – 12 total central banks and 24 supportive branches. The Lightning Network, however, allows anyone to open a channel without any permission required. The prompt for the question was the number of nodes and channels popping up on the Lightning Network. There is a difference in the security of banks and Bitcoin – with Bitcoin requiring public and private keys, making it more secure than the fiat currency bank’s single symmetrical key requirement, it was underlined during the event. LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), a fintech company focused on the creation of enterprise-grade infrastructure to drive bitcoin adoption, has developed lqwd.tech, the company’s proprietary platform as a service (“PaaS”) that allows users to execute transactions on the Lightning Network instantly, securely, and with fewer fees. Since the June 2021 acquisition, LQwD has cumulatively acquired over C$9,000,000 (US$7.19 million) worth of Bitcoin as both a reserve and operating asset for the company, some of which is already being used on the Lightning Network. The company’s holdings is around 150 Bitcoin at this time. LQwD has also entered into two strategic service agreements, one with the leading Canadian crypto trading platform Netcoins, Inc., a subsidiary of BIGG Digital Assets Inc., and the other with Breez Development Ltd., an Israeli-based Lightning Network wallet provider. “I wanted to take a moment to recap what has been an active six months for LQwD since listing in June,” LQwD CEO Shone Anstey said (https://ibn.fm/PCuB7). “The remarkable growth of the Lightning Network has validated LQwD’s reason to be hyper-focused on Lightning, and I look forward to continuing to expand our business on this rapidly growing global payment network.” The remarkable growth that Anstey speaks of refers to the multiple milestones reached by the Lightning Network since January 2021, including:

• Node growth of 105% from 770 to 15,000 established nodes
• A Bitcoin capacity increase of 160% (from 1,125 BTC to almost 3,000 BTC)
• Payment channels reached up to 92% established, from 38,000 to 73,000 payment channels

LQwD is now hyper-focused in 2022 on continuing its expansion and on the rapidly growing global payment network. The company expects cryptocurrency’s popularity to continue growing and the Lightning Network to become a force for change worldwide and the global monetary exchange of the future. For more information, visit the company’s website at www.LQwDFinTech.com. NOTE TO INVESTORS: The latest news and updates relating to LQWDF are available in the company’s newsroom at https://ibn.fm/LQWDF

• Canadian-based clean energy solutions innovator FuelPositive Corp. is developing a means of producing and using ammonia as a non-carbon polluting fuel source
• FuelPositive regards the green ammonia produced by its unique system as a safer and more effective means of transporting hydrogen that can be used to provide power and other benefits in an environmentally positive manner
• The agricultural and shipping industries are preferred targets for conversion because of their heavy carbon fuel use, and some companies are already preparing to transition away from fossil fuels as viable alternatives become available
• The portability of FuelPositive’s solution also makes it an ideal means of providing energy to underserved, remote parts of the planet

As clean energy solutions innovator FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) nears launch of its initial proprietary modular system for producing green ammonia, the competition to advance green ammonia technology as a potential alternative to existing greenhouse gas-emitting fuel sources is heating up. A Yale School of the Environment report this month (https://ibn.fm/a2p1n) noted that experimental green ammonia-producing plants powered by large wind or solar farms have been operating in Britain and Japan since 2018, another is planned in the United States by 2023, an Australia plant is aiming to produce 3,500 tons of green ammonia annually by the end of this year, and a Saudi Arabia plant aims to generate 1.2 million tons of it by 2025. In addition, there is the ‘world’s largest green ammonia plant’ planned for South Africa, set to go live in 2025 (https://ibn.fm/oQPT8). “This is a very dynamic field; there’s news out every day,” Melbourne, Australia’s Monash University chemist Douglas Macfarlane stated in the report. Macfarlane, like FuelPositive’s core team, has been working to develop new and much more efficient ways of making green ammonia. FuelPositive’s prototype systems will be fully portable when they roll out later this year with targeted capacity of producing up to 300 kilograms per day of liquid anhydrous green ammonia, which is the approximate amount needed to fertilize and power an 1,800-acre farm. But the output can be increased (or decreased) based on the end user requirements, according to the company, because of the system’s modular and scalable design (https://ibn.fm/CKVNA). One end target is to store hydrogen as green ammonia for effective transportation and storage, with the option of easy conversion back to hydrogen for use in hydrogen fuel cells and other pure hydrogen applications. (FuelPositive’s green ammonia stores 65% more hydrogen than highly compressed pure hydrogen, per unit of storage) Hydrogen is widely regarded as the optimal alternative fuel for weaning industries and consumers off polluting carbon-energy sources that continue to threaten global quality of life amid ongoing climate change. The combustion of 100% green ammonia is also the focus of many studies around the world. The agriculture industry uses about 80 percent of the ammonia produced each year applying carbon-intensive methods for nitrogen-rich fertilizer that improves plant nutrition and crop quality, and ultimately preserves soil fertility, when used properly. (https://ibn.fm/8VcqT). Switching to green ammonia could be transformative for the industry, driving down farming’s carbon footprint by as much as 90 percent for corn and small grain crops, according to the Yale school report. The transition could benefit other industries as well, the consumer product transport industry in particular. A report last year by the International Energy Agency predicted that ammonia will be vital for the shipping industry, which is currently responsible for 3 percent of global emissions (https://ibn.fm/odaVh). Shipping carrier Hoegh Autoliners announced Jan. 20 that it has ordered up to 12 LNG-fueled pure car and truck Aurora-class ships that will be suitable to retrofit to ammonia or methanol propulsion in keeping with its plans to make them the first in the carrier segment to run on green ammonia (https://ibn.fm/54SnU), signaling the industry’s serious intention to explore more environmentally friendly activity. FuelPositive’s modular, scalable platform is also being touted as a solution for providing energy to remote communities thanks to the technology’s portability and efficiency. “Our (Hydrogen-Ammonia Synthesizer) systems are small, they’re about the size of a shipping container that you would see on an ocean-going ship, and we can move them all over the place. So they can be used exactly where the ammonia is needed, so we don’t have to transport ammonia all over the place,” CEO Ian Clifford told a group of young investment advisers last fall (https://ibn.fm/PnbBO). “We think our company will grow a lot in value over the next six to 12 months as our systems are delivered to end users — the people who need the ammonia.” For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• Upcoming study supports CYBN’s mission to develop psychedelics into therapeutics.
• Kernel Flow uses pulsed light instead of continuous wave light to increase measured brain information.
• Study may provide crucial “mind-imaging” information that has been previously missing.

Cybin (NEO: CYBN) (NYSE American: CYBN) is starting off the new year right — the company has received approval from an Institutional Review Board (“IRB”) for a feasibility study using Kernel’s quantitative neuroimaging technology, Kernel Flow. Enrollment for the study begins early this year (https://ibn.fm/XTXAe). “By leveraging the Kernel Flow technology, we may have the ability to measure longitudinal brain activity before, during and after a psychedelic experience, and collect quantitative data as opposed to subjective patient reporting,” said Cybin CEO Doug Drysdale. “We believe the results of this study will lead to future studies that will test the effectiveness of psychedelic treatments and will further support our mission to develop psychedelics into therapeutics.” The feasibility study is designed to utilize Kernel’s Flow technology to evaluate ketamine’s psychedelic effect on cerebral cortex hemodynamics (https://ibn.fm/YeDwV). This study could provide crucial information that “may lead to new frontiers in psychedelic therapeutics by enabling the acquisition of longitudinal brain activity before, during and after a psychedelic experience, providing quantification of what was previously subjective patient reporting,” the company noted. “The word psychedelic means ‘mind-manifesting,’ but what has been missing is useful ‘mind-imaging’—the ability to dynamically trace the neural correlates of human conscious experience,” explained Cybin’s chief clinical officer, Dr. Alex Belser. “Conventional neuroimaging just isn’t dynamic enough to study the psychedelic experience in the brain as it happens. This study of ketamine’s psychedelic effects while wearing headgear equipped with sensors to record brain activity could open up new frontiers of understanding.” Kernel’s exclusive tech, called Kernel Flow, uses pulsed light instead of continuous wave light to increase measured brain information. The device used to measure the information is easily wearable, which is a significant difference from electroencephalography (“EEG”) electrodes that typically require gel on the head or functional magnetic resonance imaging (“fMRI”) studies that require a participant to lie in a scanner. The entire system is the size and look of a bicycle helmet and could, in the future, be more broadly used for neuroscientific or physiological studies of brain activity during psychedelic use, noted Cybin. “Quantitatively measuring the brain within the context of a psychedelic experience is a promising frontier,” said Kernel founder and CEO Bryan Johnson. “With Kernel Flow, Cybin’s researchers can start putting numbers and quantification to subjective states of mind, including altered ones.” As a sponsor of the study, Cybin retains an exclusive interest in any innovations that are discovered or developed through its independent analysis of the study findings. Kernel will hold the same rights relating to its Kernel technology. “We hope this feasibility study can bridge the gap of real-time quantitative data collection during psychedelic treatments to further understand the correlation of effects from these powerful molecules,” said Drysdale. “The ability to access real-time brain activity data during a psychedelic experience has tremendous potential for the development of future psychedelic therapeutics.” Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Chris Bunka, the Chairman and CEO of Lexaria, featured on the EDGE podcast hosted by Brandon C. White
• He provided insight into his background, professional philosophies, and Lexaria’s operations, with a focus on the company’s patented DehydraTECH(TM) technology
• Mr. Bunka also advised small companies and entrepreneurs, citing the importance of understanding the competitive environment

Chris Bunka, the Chairman and Chief Executive Officer (“CEO”) of Lexaria Bioscience (NASDAQ: LEXX), was recently featured on episode 234 of the EDGE Podcast. Hosted by Brandon C. White, an Angel Investor and Entrepreneur, Mr. Bunka shared insights into his professional journey while also sharing what the company is committed to achieving going forward. Mr. Bunka lauded the company’s patented DehydraTECH(TM) technology, citing how integral it is to improve the delivery of active pharmaceutical ingredients and other fat-soluble molecules.  So far, this technology has proven promising for the potential treatment of hypertension and heart disease, and is already being sublicensed for the delivery of CBD. “Our technology is all about enabling a much higher fraction and a much smoother delivery of the beneficial substances in the foods you eat and in the drugs you take and, quite frankly, getting them into your bloodstream,” he noted (https://ibn.fm/kGRDm). He also walked the audience through his career growth that spans over four decades, having started his first business at the age of 17. Over the years, he notes, he has learned how to run a business, rely on other people, and manage employees, skills that have translated to the success of Lexaria thus far. When asked about his most significant career lessons, Mr. Bunka reckoned that while he has learned a lot, the central aspect is the significance of understanding the competitive environment. He further advised small companies and entrepreneurs first to understand their competitive environment and then understand the products and services they offer to customers. “A lot of small companies don’t do a good job of understanding their competitive environment,” he noted. “A lot of them say, ‘I’m the best, I’m the fastest.’…I could be on my laptop and have somebody pitching me on an idea, and I see 3,700 companies just like his. It makes it really hard, so understanding your competitive environment is really, really important, as well as understanding your products and services,” he added. The interview with Mr. Bunka offered a glimpse into the inner workings of Lexaria, the vision that he has for the company, and the goals that it is working towards. In addition, he talked about the company’s ongoing efforts to make the most out of its innovative delivery platform, along with professional philosophies that have guided his career so far. You can listen to the entire interview here https://ibn.fm/3QMBD For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• NLR reports that bipartisan support for cannabis policies could reshape federal enforcement, set the stage for further state legalization
• GOP sponsorship of bills could mean greater likelihood of success
• SGMD’s strategic plan is centered on expanding end-market access as a central player in the growing California cannabis delivery marketplace

As 2021 wound to a close, indications of bipartisan support for federal cannabis reform raised the hope that legislative progress may be made on the federal level in the coming year (https://ibn.fm/LMlBO). Companies operating in the cannabis space, including Sugarmade (OTC: SGMD), are watching closely to see if that hope is realized. “Long-anticipated federal cannabis reform may be on the horizon,” stated a December 2021 article in the National Law Review. “In the last month, bipartisan governors and groups from both bodies of Congress have established support for cannabis policies that would reshape federal enforcement and set the stage for further state legalization.” The article specifically noted the States Reform Act, which was introduced by South Carolina Representative Nancy Mace in November; the act is the first Republican-backed cannabis decriminalization bill with support from four other Republican representatives. “The bill would amend several existing laws, but most significantly would remove cannabis from the list of Schedule 1 controlled substances, effectively ending federal cannabis prohibition,” NLR reported. “The bill defers to states to enact additional regulations but establishes some baseline federal policies,” the article continued. “The cannabis market would be overseen by various existing federal agencies: cannabis growers by the U.S. Department of Agriculture, cannabis products by both the Bureau of Alcohol, Tobacco, Firearms and Explosives and the Alcohol and Tobacco Tax and Trade Bureau, and all medical use by the Food and Drug Administration. A 3% excise tax would also apply to all cannabis products, and the tax revenue would in part support law enforcement initiatives, veterans’ mental health programs, and U.S. Small Business Administration (“SBA”) investment in cannabis businesses. “While this broad federal decriminalization agenda is just getting off the ground in the House, its GOP-sponsorship may carry a greater likelihood of success at both the House and Senate level, where other, more progressive Democratic bills have failed,” the article concluded. Sugarmade is a product and branding marketing company investing in operations and technologies with disruptive potential. The company’s core strategic plan is centered on expanding its end-market access as a central player in the growing California cannabis delivery marketplace while developing its in-house cannabis production capacity to verticalize operations in the space. Through a combination of organic growth and strategic acquisitions, Sugarmade intends to develop a full farm-to-door vertically integrated cannabis business. For more information, visit the company’s website at www.Sugarmade.com. NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SGMD

• Growth Capital Acquisition Corp. agreed to combine with Cepton Technologies Inc, a Silicon Valley firm focused on the development of lidar technology in August 2021
• The deal, which is expected to close on February 9, 2022, will value the company at approximately $1.5 billion on a cash-free, debt-free basis
• GCAC’s management, Prokopios (Akis) Tsirigakis and George Syllantavos, have previously listed and successfully concluded 3 SPAC deals and boast a lengthy and experienced track record within the industry

Growth Capital Acquisition (NASDAQ: GCAC), a publicly traded special purpose acquisition company (“SPAC”) listed on February 2, 2021, with $172.5 million in trust, arrived at a definitive business combination agreement with Cepton Technologies Inc., a Silicon Valley innovator and leader in high performance MMT(R) lidar solutions, on August 5, 2021. The proposed deal, which is expected to be completed early on February 9, 2022, will see the company renamed as Cepton Inc and listed on the Nasdaq stock exchange under new ticker symbol ‘CPTN’, subject to, among other things, approval by Growth Capital’s stockholders (https://ibn.fm/yfgYP). The transaction values Cepton at an enterprise value of approximately $1.5 billion on a cash-free, debt-free basis, and is expected to provide the newly combined company with approximately $231 million in gross proceeds, consisting of $172.5 million from Growth Capital and a further $58.5 million from a PIPE (‘Private Investment in Public Equity’) offering. Since its founding in 2016, Cepton has gone on to become a key player in the field of ADAS (“Advanced Driver-Assistance Systems”), the largest end-market for lidar. The company’s relentless focus on lidar technology as well as its proprietary directional lidar technology, known as MMT(R) (“Micro Motion Technology”) led the company to be awarded the largest-ever ADAS lidar series production award seen thus far by General Motors on July 13, 2021. A mere fortnight later, Ford Motor Company also published an article stating that they were engaging with Cepton and their custom LiDAR technology for some of its automobiles’ advanced ADAS features (https://ibn.fm/FQi1Q). Cepton Technologies’ state-of-the-art technology and robust commercial prospects were certainly at the forefront of Growth Capital Acquisition Corp’s management’s minds when opting to pursue the current business combination. Led by Chairman and Co-CEO, Prokopios (Akis) Tsirigakis and Co-CEO and CFO, George Syllantavos, GCAC’s management boast a handsome pedigree within the SPAC universe, having already founded, listed, and closed on three separate SPAC-based business combinations over the past few years. Prior to his work with GCAC and other SPACs, Mr Tsirigakis served as the CEO of Star Bulk (NASDAQ: SBLK) a company that owns and manages  dry bulk vessels, and Combine Marine Inc., a ship management company. Meanwhile, Mr. Syllantavos previously advised on the coordination and listing of the Hellenic Telecommunications Organization S.A. and has served as a financial and strategic advisor to both, the Greek Ministry of Industry & Energy, and the Greek Ministry of Health in the past. The pair have also benefitted from stellar performance from prior deals. Having initially listed the Stellar Acquisition III, Inc (NASDAQ: STLR) SPAC on August 16, 2016, Mr. Tsirigakis oversaw the vehicle’s merger with Phunware, Inc – a mobile apps company on December 26, 2018. Whilst Mr. Tsirigakis stepped down as CEO post the deal, the combined entity would go on to soar by over 2,000 percent in the month following the deal. Similarly, Mr. Syllantavos helped list blank-check vehicle ITHAX Acquisition Corp (NASDAQ: ITHX) in January 2021, with the company recently revealing that it had agreed to merge with Mondee, Inc, a California-based travel company in a deal valued at approximately $1 billion. For more information, visit the company’s website at www.GCACorp.com NOTE TO INVESTORS: The latest news and updates relating to GCAC are available in the company’s newsroom at https://ibn.fm/GCAC

• NMRD appoints UK-based Dr. Arash Ghadar as Chief Operating Officer, brings decades of healthcare and technology experience
• Dr. Ghadar previously supervised product development lifecycles, feasibility studies, prototyping, validation, quality management, volume manufacturing, certification
• NMRD commercializing sugarBEAT(R) non-invasive, flexible, CGM device, recently completed initial shipment to UK licensee MySugarWatch Limited
• MySugarWatch Limited aims to market devices via subscription-based diabetes coaching and management service

Nemaura Medical (NASDAQ: NMRD), a medical technology company developing affordable non-invasive wearable diagnostic devices and digital tools for chronic disease management, recently appointed Dr. Arash Ghadar as Chief Operating Officer (https://ibn.fm/tj1TZ). Dr. Ghadar brings decades of UK-based technical and healthcare management experience to Nemaura, including his current non-executive director role at Medilink Midlands – the Midlands Life Sciences industry association – where he aims to advance the Midlands life science sector. “I am delighted to join Nemaura, a company with a world-class ambition to transform people’s lives,” said Dr. Ghadar. “I very much look forward to working with management and the wider team to successfully commercialize the transformational line of non-invasive products the company is developing, beginning with our continuous glucose monitoring devices and sensors for patients with diabetes. Dr. Ghadar holds BSc and Masters degrees in Electronics and Control Systems Engineering and a Ph.D. in Biosensors from The University of Warwick. He brings a decade of healthcare and technical management experience to Nemaura from his previous tenure as Technical Director at Datalink Electronics. In that role, Dr. Ghadar managed daily operations, legal affairs, business planning, finance, sales, and business development of the design team. Dr. Ghadar’s also supervised numerous healthcare and industrial-related projects, including product development lifecycles, design, development, feasibility studies, prototyping, validation, quality management, volume manufacturing, and certification. “Ash will play an important role at Nemaura as we begin to scale up our manufacturing and distribution operations,” said Nemaura CEO Dr. Faz Chowdhury. “He brings over 20 years of product development, management and leadership experience spanning both business and technical disciplines. His main area of expertise is in the medical devices sector, and primarily within a contract design and manufacturing setting. That will be a true asset for the company during the commercialization phase of our growth.” NMRD is currently commercializing its sugarBEAT(R) non-invasive, flexible, and affordable continuous glucose monitoring (“CGM”) device in the UK. The company has begun shipment of devices and sensors to MySugarWatch Limited as part of an order of 5,000 CGM devices and 200,000 sensors. Plans to market the devices include a subscription-based diabetes coaching and management service aimed at nearly 5 million diabetics and 13.6 million people at increased risk of contracting Type 2 diabetes in the UK (https://ibn.fm/NTskI). In addition, NMRD recently launched beta trials of Miboko, its new metabolic health program for use by employers and insurers worldwide (https://ibn.fm/Yd5xE), which has started to gain strong traction. The company plan a large scale marketing campaign to grow this subscription based business. Founded in 2011, NMRD first developed a single platform technology to measure blood markers at the skin’s surface. The company since evolved the technology to address a global need for wearable glucose-monitoring devices at the intersection of diabetes, pre-diabetes, and weight loss markets. With several filed and pending patents, along with substantial trade secrets covering its technology platform, Nemaura is positioned favorably within the rapidly growing wearable diagnostic device industry. For more information, visit the company’s website at www.NemauraMedical.com. NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

• PlantX recently launched ‘Medically Speaking,’ a new YouTube series aimed at promoting plant-based education by dispelling myths and misconceptions around plant-based living
• Host Adam Kruger will engage experienced healthcare professionals with a passion for promoting plant-based living and wellness
• The series is part of various education initiatives geared toward making plant-based living more accessible

The digital face of the plant-based community, PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), has launched a new YouTube series titled ‘Medically Speaking’ intended to promote plant-based education and offer consumers the necessary knowledge-based resources to help them attain their plant-based objectives. “‘Medically Speaking’ is designed as an informative series that centers around conversations with the PlantX Medical Advisory Board on plant-based topics. Beyond providing evidence-based information to clarify potential questions and knowledge gaps in the plant-based space, the series also aims to offer creative solutions to overcoming plant-based challenges as approved and discussed by trusted healthcare professionals,” explained PlantX in a news release announcing the launch (https://ibn.fm/PJUUA). In the first episode, which went live on January 20, host Mr. Adam Kruger engaged Dr. Edward Tam, a clinical hepatologist (liver expert) based in Vancouver, British Columbia. In highlighting the proven benefits of a plant-based lifestyle, Dr. Tam touched the non-alcoholic fatty liver disease, a condition attributable to lifestyle choices, noting that medical literature has evidenced that a more plant-based diet can be healthy for the liver and general wellbeing. Dr. Tam also dispelled the myth that adopting a plant-based lifestyle needs an all-or-nothing approach, underlining that making incremental changes to one’s diet as one journeys gradually toward a 100% plant-based diet “makes sense.” It eliminates the challenges associated with an abrupt shift from an omnivorous diet to 100% plant-based. According to Dr. Tam, this gradual approach leads to a more sustainable change. In addition, Dr. Tam shared the advice he offers patients attempting to modify their lifestyles. “I think that people are just used to the way they have always eaten. People are not opposed to change. It’s just that they haven’t really thought about it much, and they haven’t been presented with the thought of making change and what possible benefits can come along. For me, [while] counseling patients and asking them to consider a different way of eating, it’s more about introducing the idea of making the change and talking about what’s going to happen at the end of that – a healthier life,” Dr. Tam added, further highlighting that his counsel aims to give patients the steps to get there. You can watch the full episode here https://www.youtube.com/watch?v=RQDWD5htUtw. This interactive discussion is the first of many others that are also part of the new series. The episodes will focus the conversation around high-impact and novel topics, discussing how plant-based lifestyles can improve health and wellbeing. As part of the series, Kruger will engage guests drawn from PlantX’s Medical Advisory Board, with the first season featuring experienced healthcare professionals with a passion for promoting plant-based living and wellness. Besides Dr. Edward Tam, other guests include Amy Gensel, a registered dietitian; Dr. Paul Gross, a family physician; and Dr. Eva Weinlander, a clinical professor and family physician. “As the interest in plant-based diets increases, so does the need and demand for engaging plant-based educational opportunities. ‘Medically Speaking’ was created as a dynamic and evidence-based educational tool that can explain plant-based myths and misinformation and empower people to overcome barriers to change,” commented PlantX Founder Sean Dollinger. The new series feeds into the company’s strategy to leverage education to make the plant-based lifestyle more accessible. Consumers interested in starting out on the plant-based journey can also access a vast library of online videos offering tips from experts and showcasing delicious plant-based recipes from different locales. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• Canada-based Flora Growth Corp. operates cannabis cultivation and extraction processes in-house at its Cosechemos lab and growth facility in central Colombia
• The company has been building a portfolio of cannabis and wellness products and obtaining a variety of licenses and GMP certifications as it establishes partnerships to economically distribute its portfolio worldwide
• Flora Growth recently announced the addition of pioneering cannabis genetics innovator Derek Pedro in an advisory role for its Cosechemos facility
• Pedro will help the company build on its more-than-190 product offerings with cannabis flower cultivation and distribution

Cannabis cultivator and worldwide cannabidiol (“CBD”) brand builder Flora Growth (NASDAQ: FLGC) is continuing to aggressively build a collective of plant-based wellness and lifestyle brands in 2022. The company recently announced its excitement over appointing renowned cannabis industry pioneer Derek Pedro as an advisor to its in-Colombia cultivation facility. Flora Growth operates the diverse business divisions of cosmetics, hemp textiles, and food and beverage products, all of which contain cannabis derivatives supplied by the Cosechemos facility in central Colombia where conditions are naturally conducive to growing and harvesting cannabis year-round. Pedro will build on the facility’s existing register of high-THC and high-CBD strains to bring to market uniquely Colombian cannabis flower that will serve both domestic and international markets for pharmaceuticals, cosmetics and nutraceuticals, according to the company’s statement. “As an internationally recognized industry expert and innovative cultivator, the appointment of Derek Pedro aligns perfectly with our goals to optimize our expanding Cosechemos facility operations and increase our varietal offering of cannabis flowers,” Flora Growth President and CEO Luis Merchan stated (https://ibn.fm/Iv4WO). “Mr. Pedro has a well-earned reputation as one of the world’s leading experts on cannabis cultivation, and we are thrilled to have him join us as we develop our growing portfolio of brands and expand our global distribution.” Pedro, who has consulted internationally on cannabis genetics and commercialized more than 50 strains within the legal Canadian market, including his wildly successful high-THC strain “Pedro’s Sweet Sativa,” described the Cosechemos facility as “one of the most beautiful and well-designed EU-GMP built processing facilities I have visited across the world.” Flora Growth owns a 90 percent interest in Cosechemos (correcting a recent news release erroneously stating the facility is wholly owned). Cosechemos is a 100-hectare (about 247-acre) site regarded as ideally situated for cultivation conditions and therefore a means of helping Flora Growth to preserve an economically efficient bottom line with growing costs estimated at about 6 cents per gram of dried product, contrasting with the 50 cents to $2 per gram reported in the United States (https://ibn.fm/h1PrT). “I am excited to join this talented team, contributing to the management of Cosechemos’ large-scale grow in Colombia. … We look to match both EU-GMP export capabilities with some of the most successful and sought-after genetics that were designed to be grown in equatorial Colombia,” Pedro stated. Flora Growth already distributes more than 190 cannabis-derivative products through e-commerce and a variety of retail partners. For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC